Today is 2020-07-15

Study for the clinical characteristics of novel coronavirus pneumonia (COVID-19)
download

注册号:

Registration number:

ChiCTR2000030464 

最近更新日期:

Date of Last Refreshed on:

2020-03-02 

注册时间:

Date of Registration:

2020-03-02 

注册号状态:

预注册  

Registration Status:

Prospective registration  

注册题目:

新型冠状病毒感染性肺炎(COVID-19)临床特征的研究 

Public title:

Study for the clinical characteristics of novel coronavirus pneumonia (COVID-19) 

注册题目简写:

 

English Acronym:

 

研究课题的正式科学名称:

新型冠状病毒感染性肺炎(COVID-19)临床特征的研究 

Scientific title:

Study for the clinical characteristics of novel coronavirus pneumonia (COVID-19) 

研究课题代号(代码):

Study subject ID:

 

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

 

申请注册联系人:

郭成贤 

研究负责人:

郭成贤 

Applicant:

Chengxian Guo 

Study leader:

Chengxian Guo 

申请注册联系人电话:

Applicant telephone:

+86 0731-88618338 

研究负责人电话:

Study leader's telephone:

+86 0731-88618338 

申请注册联系人传真 :

Applicant Fax:

 

研究负责人传真:

Study leader's fax:

 

申请注册联系人电子邮件:

Applicant E-mail:

gchxyy@163.com 

研究负责人电子邮件:

Study leader's E-mail:

gchxyy@163.com 

申请单位网址(自愿提供):

Applicant website(voluntary supply):

 

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

 

申请注册联系人通讯地址:

湖南省长沙市岳麓区桐梓坡路138号 

研究负责人通讯地址:

湖南省长沙市岳麓区桐梓坡路138号 

Applicant address:

138 Tongzipo Road, Yuelu District, Changsha, Hu'nan, China 

Study leader's address:

138 Tongzipo Road, Yuelu District, Changsha, Hu'nan, China 

申请注册联系人邮政编码:

Applicant postcode:

 

研究负责人邮政编码:

Study leader's postcode:

 

申请人所在单位:

中南大学湘雅三医院 

Applicant's institution:

The Third Xiangya Hospital, Central South University 

是否获伦理委员会批准:

是 

Approved by ethic committee:

Yes 

伦理委员会批件文号:

Approved No. of ethic committee:

2020-S022 

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

中南大学湘雅三医院伦理委员会 

Name of the ethic committee:

Institutional Review Board of the Third Xiangya Hospital of Central South University 

伦理委员会批准日期:

Date of approved by ethic committee:

 

伦理委员会联系人:

王博士 

Contact Name of the ethic committee:

Dr. Wang 

伦理委员会联系地址:

湖南省长沙市岳麓区桐梓坡路138号中南大学湘雅三医院 

Contact Address of the ethic committee:

The Third Xiangya Hospital, Central South University, 138 Tongzipo Road, Yuelu District, Changsha, Hu'nan, China 

伦理委员会联系人电话:

Contact phone of the ethic committee:

 

伦理委员会联系人邮箱:

Contact email of the ethic committee:

 

研究实施负责(组长)单位:

中南大学湘雅三医院 

Primary sponsor:

The Third Xiangya Hospital, Central South University 

研究实施负责(组长)单位地址:

湖南省长沙市岳麓区桐梓坡路138号 

Primary sponsor's address:

138 Tongzipo Road, Yuelu District, Changsha, Hu'nan, China 

试验主办单位(项目批准或申办者):

Secondary sponsor:

经费或物资来源:

国家自然科学基金 

Source(s) of funding:

National Natural Science Foundation of China 

研究疾病:

新型冠状病毒肺炎(COVID-19) 

Target disease:

Novel Coronavirus Pneumonia (COVID-19) 

研究疾病代码:

 

Target disease code:

 

研究类型:

流行病学研究 

Study type:

Epidemilogical research 

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study 

研究目的:

了解新冠的临床特征 

Objectives of Study:

To study the clinical characteristics of COVID-19 

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

研究设计:

连续入组 

Study design:

Sequential 

纳入标准:

新型冠状病毒肺炎(COVID-19)患者 

Inclusion criteria

Novel Coronavirus Pneumonia (COVID-19) patients 

排除标准:

无 

Exclusion criteria:

NO 

研究实施时间:

Study execute time:

From2020-03-03To 2020-04-01 

干预措施:

Interventions:

组别:

Case series

样本量:

200

Group:

Case series

Sample size:

干预措施:

Nil

干预措施代码:

Intervention:

Nil

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

测量指标:

Outcomes:

指标中文名:

临床特征

指标类型:

主要指标 

Outcome:

Clinical characteristics

Type:

Primary indicator 

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

盲法:

N/A

Blinding:

N/A

试验完成后的统计结果(上传文件):

Calculated Results ater
the Study Completed(upload file):

原始数据公开时间:

The time of sharing IPD:

Real time access

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

联系研究者

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Contact researchers

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic Data Capture, EDC

数据管理委员会:

Data Managemen Committee:

有/Yes

注册人:

Name of Registration:

 2020-03-02
return list